Page 58 - Read Online
P. 58

Page 8 of 14                                  Stenina-Adognravi et al. Vessel Plus 2018;2:30  I  http://dx.doi.org/10.20517/2574-1209.2018.40
























               Figure 2. Interaction of hyperglycemia-regulated thrombospondin (TSP) pathways. TSP-4 increases recruitment of macrophages, while
               TSP-1 is needed for the resolution of inflammation. In response to hyperglycemia, TSP-1 levels are downregulated by increased levels of
               miR-467. TSP-4 is upregulated as a result of upregulation of TGF-β and activation of SMAD3. Upregulation of TSP-4 result in increased
               recruitment of macrophages into the tumor. In the absence of TSP-1 and resolution of inflammation, the accumulation of macrophages
               increases. In a feedback loop, TSP-4 increases the levels of an inhibitory TGF-β receptor beta-glycan. TGF-β further decreases the
               production of TSP-1. In a feedback loop, TSP-1 is an activator of TGF-β. Green arrow and text = upregulation in response to hyperglycemia;
               red arrow and text = downregulation in response to hyperglycemia. TGF-β: transforming growth factor beta




               While multiple targets may potentiate the effects of modulation of TSP expression and functions, the
               complexity of TSP interactions requires an unbiased testing of the effects of potential anti-cancer therapies
               in in vivo models. When the interactions and mechanisms are dissected and understood, TSPs may become
               desirable targets for the integrative anti-cancer approaches.


               DECLARATIONS
               Authors’ contributions
               Analyzed the literature, collected the references: Muppala S, Gajeton J, Stenina-Adognravi O
               Prepared a draft of the manuscript: Muppala S, Gajeton J
               Prepared the final version of the manuscript: Stenina-Adognravi O


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               The work on this review has been supported by funds from NIH to Olga Stenina-Adognravi (RO1 HL117216
               and RO1 CA177771) and from the American Heart Association to Jasmine Gajeton/Olga Stenina-Adognravi
               (17PRE33660475).

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.
   53   54   55   56   57   58   59   60   61   62   63